207 related articles for article (PubMed ID: 20678069)
1. Tau pathology and future therapeutics.
Gozes I
Curr Alzheimer Res; 2010 Dec; 7(8):685-96. PubMed ID: 20678069
[TBL] [Abstract][Full Text] [Related]
2. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
3. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
6. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
8. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y; Gozes I
Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
[TBL] [Abstract][Full Text] [Related]
9. Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity.
Fu YJ; Nishihira Y; Kuroda S; Toyoshima Y; Ishihara T; Shinozaki M; Miyashita A; Piao YS; Tan CF; Tani T; Koike R; Iwanaga K; Tsujihata M; Onodera O; Kuwano R; Nishizawa M; Kakita A; Ikeuchi T; Takahashi H
Acta Neuropathol; 2010 Jul; 120(1):21-32. PubMed ID: 20140439
[TBL] [Abstract][Full Text] [Related]
10. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
Ono M; Sahara N; Kumata K; Ji B; Ni R; Koga S; Dickson DW; Trojanowski JQ; Lee VM; Yoshida M; Hozumi I; Yoshiyama Y; van Swieten JC; Nordberg A; Suhara T; Zhang MR; Higuchi M
Brain; 2017 Mar; 140(3):764-780. PubMed ID: 28087578
[TBL] [Abstract][Full Text] [Related]
11. New insights into genetic and molecular mechanisms of brain degeneration in tauopathies.
Forman MS; Lee VM; Trojanowski JQ
J Chem Neuroanat; 2000 Dec; 20(3-4):225-44. PubMed ID: 11207421
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative tauopathies.
Lee VM; Goedert M; Trojanowski JQ
Annu Rev Neurosci; 2001; 24():1121-59. PubMed ID: 11520930
[TBL] [Abstract][Full Text] [Related]
13. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
14. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
[TBL] [Abstract][Full Text] [Related]
15. Cellular and regional vulnerability in frontotemporal tauopathies.
Forrest SL; Kril JJ; Halliday GM
Acta Neuropathol; 2019 Nov; 138(5):705-727. PubMed ID: 31203391
[TBL] [Abstract][Full Text] [Related]
16. Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.
Gozes I
EPMA J; 2010 Jun; 1(2):305-16. PubMed ID: 23199066
[TBL] [Abstract][Full Text] [Related]
17. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y; Maor-Nof M; Gozes I
PLoS One; 2019; 14(3):e0213666. PubMed ID: 30865715
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
19. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Gozes I
Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
[TBL] [Abstract][Full Text] [Related]
20. Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease.
Botez G; Probst A; Ipsen S; Tolnay M
Acta Neuropathol; 1999 Sep; 98(3):251-6. PubMed ID: 10483782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
